Therapeutics in development with the potential to both treat and prevent disease

Cambrian is developing a wide array of new therapeutics, each targeting a biological driver of aging. We work with top-tier academic institutions to create Cambrian Affiliate Companies (Affiliates) across the US and Europe.

Pipeline Highlights

As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific inventions, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then utilize them as preventative medicines to improve the overall quality of life as we age.

View our full list of programs

Program

Target Indication

Development Phase

Preclinical

Phase 1

Phase 1b/2a

Phase 2

Phase 2b

Phase 3

PipeCo

ATX-304

Obesity

Phase 1b/2a
Phase 1b/2a
Undisclosed
Phase 1b/2a
Driver: 
Therapeutic Area: 
Cardio Metabolism
Program Overview:

ATX-304 is a small molecule, combined AMPK and mitochondrial activator for cardiometabolic diseases. It is currently being studied in a Phase 1B trial in pre-diabetic, overweight / obese subjects in the European Union. In pre-clinical studies, ATX-304 demonstrated beneficial effects on glucose and lipid metabolism and energy expenditure in multiple animal models of obesity and metabolic disease, as well as on cardiovascular function and exercise endurance in aging and aged animals. Upon completion of the Phase 1B study, the Amplifier team is considering further development of ATX-304 for chronic weight management in adult patients with overweight/obesity and associated cardiometabolic disorders.

ATX-304

Obesity Associated Diseases

Phase 1b/2a
Phase 1b/2a
Undisclosed
Phase 1b/2a
Driver: 
Therapeutic Area: 
Metabolism
Program Overview:

ATX-304 is a small molecule, combined AMPK and mitochondrial activator for cardiometabolic diseases. It is currently being studied in a Phase 1B trial in pre-diabetic, overweight / obese subjects in the European Union. In pre-clinical studies, ATX-304 demonstrated beneficial effects on glucose and lipid metabolism and energy expenditure in multiple animal models of obesity and metabolic disease, as well as on cardiovascular function and exercise endurance in aging and aged animals. Upon completion of the Phase 1B study, the Amplifier team is considering further development of ATX-304 for chronic weight management in adult patients with overweight/obesity and associated cardiometabolic disorders.

TOR-101

Respiratory Tract Infections

Phase 1 Prepared
Phase 1 Prepared
Undisclosed
Phase 1 Prepared
Driver: 
Therapeutic Area: 
Respiratory Tract Infections
Program Overview:

The FDA-approved drug rapamycin and its analogues (rapalogs) are inhibitors of the mechanistic target of rapamycin (mTOR). They are an exceptionally well-explored therapeutic class, encompassing 3 FDA-approved medications evaluated in more than 3,000 clinical trials. Tornado Therapeutics is developing safer, more effective mTOR inhibitors with novel selectivity profiles to extend human healthspan. Its most advanced asset is currently moving into IND-enabling studies, while a second asset is undergoing preclinical efficacy testing.

TOR-101

Oncology

Phase 1 Prepared
Phase 1 Prepared
Undisclosed
Phase 1 Prepared
Driver: 
Therapeutic Area: 
Oncology
Program Overview:

The FDA-approved drug rapamycin and its analogues (rapalogs) are inhibitors of the mechanistic target of rapamycin (mTOR). They are an exceptionally well-explored therapeutic class, encompassing 3 FDA-approved medications evaluated in more than 3,000 clinical trials. Tornado Therapeutics is developing safer, more effective mTOR inhibitors with novel selectivity profiles to extend human healthspan. Its most advanced asset is currently moving into IND-enabling studies, while a second asset is undergoing preclinical efficacy testing.

TOR-103

Respiratory Tract Infections

Candidate
Candidate
Undisclosed
Candidate
Driver: 
Therapeutic Area: 
Respiratory Tract Infections
Program Overview:

The FDA-approved drug rapamycin and its analogues (rapalogs) are inhibitors of the mechanistic target of rapamycin (mTOR). They are an exceptionally well-explored therapeutic class, encompassing 3 FDA-approved medications evaluated in more than 3,000 clinical trials. Tornado Therapeutics is developing safer, more effective mTOR inhibitors with novel selectivity profiles to extend human healthspan. Its most advanced asset is currently moving into IND-enabling studies, while a second asset is undergoing preclinical efficacy testing.

TOR-103

Oncology

Candidate
Candidate
Undisclosed
Candidate
Driver: 
Therapeutic Area: 
Oncology
Program Overview:

The FDA-approved drug rapamycin and its analogues (rapalogs) are inhibitors of the mechanistic target of rapamycin (mTOR). They are an exceptionally well-explored therapeutic class, encompassing 3 FDA-approved medications evaluated in more than 3,000 clinical trials. Tornado Therapeutics is developing safer, more effective mTOR inhibitors with novel selectivity profiles to extend human healthspan. Its most advanced asset is currently moving into IND-enabling studies, while a second asset is undergoing preclinical efficacy testing.

TOR-104

Autoimmune Disease

Lead
Lead
Undisclosed
Lead
Driver: 
Overactive cell growth signals
Therapeutic Area: 
Program Overview:

The FDA-approved drug rapamycin and its analogues (rapalogs) are inhibitors of the mechanistic target of rapamycin (mTOR). They are an exceptionally well-explored therapeutic class, encompassing 3 FDA-approved medications evaluated in more than 3,000 clinical trials. Tornado Therapeutics is developing safer, more effective mTOR inhibitors with novel selectivity profiles to extend human healthspan. Its most advanced asset is currently moving into IND-enabling studies, while a second asset is undergoing preclinical efficacy testing.

CAM-9782

N/a: Cell Manufacturing Reagent

Candidate
Candidate
Undisclosed
Candidate
Driver: 
Therapeutic Area: 
Oncology
Program Overview:

Telovance™ is a protein complex that is delivered during the ex-vivo expansion stage of cell manufacturing. Telovance™ is designed to enhance the next generation of cell therapies and enable more sophisticated, multi-step cell engineering technologies.

All Programs

Cambrian is developing a wide array of new therapeutics, each targeting a biological driver of aging. We work with top-tier academic institutions to create Cambrian Pipeline Companies across the US and Europe.

Cardiometabolic Diseases

Fibrotic Diseases

Women's Health

Oncology

Oncology & Immunology

Rare Diseases

Cardiovascular Diseases

Rare Cardiovascular Diseases

Autoimmune & Rare Diseases

Accessibility Icon